Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.40    0.00 (0.00%)
Bid:
6.30
Ask:
6.50
Spread: 0.20 (3.175%)
Market Cap: £6.61m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Offer Document Posted

30 Jan 2014 16:37

RNS Number : 9294Y
Ducat Ventures PLC
30 January 2014
 



Ducat Ventures Plc

 

OPEN OFFER OF UP TO 203,380,942 NEW ORDINARY SHARES

AT £0.0004 PER SHARE

 

Ducat Ventures Plc (the "Company") announces an Open Offer to those members who were on the register at 18th November 2013 and the Company has today posted the Open Offer document (which can be found on the Company's website at www.ducatventures.co.uk) to all shareholders.

The letter from the Chairman which forms part of the Open Offer document is set out below.

 

30 January 2014

 

 

Enquiries:

Ducat Ventures plc

Nicholas Nelson

07921 522 920

Cairn Financial Advisers LLP

Liam Murray / Jo Turner

020 7148 7900

Peterhouse Corporate Finance Ltd

Lucy Williams/ Fungai Ndoro

020 7469 0936

 

 

LETTER FROM THE CHAIRMAN OF DUCAT VENTURES PLC

 (Incorporated and registered in England and Wales with registered number 05880755)

 

Directors:

Mr Adam Reynolds (Executive Chairman)

Mr Nicholas Nelson (Non-Executive Director)

 

Registered Office:

145-147 St. John Street

London

EC1V 4PY

 

 

 

To Shareholders (and for information purposes to the holders of warrants and options in the Company)

OPEN OFFER OF UP TO 203,380,942 NEW ORDINARY

SHARES AT £0.0004 PER SHARE

 

Introduction

Following the passing of the resolutions at the Company's general meeting held on 18 November 2013 and as set out in the Company's circular to shareholders dated 1 November 2013, the Company is proposing to raise up to £81,352 through an open offer of Ordinary Shares to Shareholders whose names appear on the register of members of the Company on the Record Date. So as to be as democratic as possible to all Shareholders on the register prior to the placing undertaken by the Company in November 2013, the Board decided to structure the open offer in this way.

The proceeds of the Open Offer will be used to provide additional working capital for the Company.

Subscribers to the Open Offer shares will also be granted one warrant for every one Open Offer share subscribed for, exercisable at a price of £0.0004 per warrant, at any time up to three years from issue.

The purpose of this document is to set out the background to, and relevant information in connection with, the Open Offer.

Potential dilution of shareholdings of Shareholders

On completion of the Open Offer the issued ordinary share capital of the Company will be increased by approximately 22.7 per cent., resulting in an immediate dilution of approximately 18.5 per cent. in aggregate for holders of Existing Ordinary Shares, save to the extent that they subscribe for their Open Offer Entitlement.

Details of the Open Offer

The Company is raising up to £81,352 (before expenses) by the issue of up to 203,380,942 New Ordinary Shares. Qualifying Shareholders may participate in the Open Offer at the Offer Price, payable in full on application.

Qualifying Shareholders may apply for any number of Offer Shares under the Open Offer calculated on the following basis:

(a) 3 Offer Shares for every 2 Existing Ordinary Shares held by Qualifying Shareholders at the Record Date (or any lesser number); and

(b) further Offer Shares in excess of their Open Offer Entitlement through the Excess Application Facility (although such Offer Shares will only be allotted to the extent that not all Qualifying Shareholders apply for their Open Offer Entitlement in full).

Once subscriptions by Qualifying Shareholders under their respective Open Offer Entitlements have been satisfied, the Company shall, in its absolute discretion, determine whether to meet any excess applications in full or in part and no assurance can be given that applications by Qualifying Shareholders under the Excess Application Facility will be met in full, in part or at all. The Offer Shares must be paid for in full on application. The latest time and date for receipt of completed Application Forms and payment in respect of the Open Offer is 11 a.m. on 14 February 2014.

The Open Offer is not being made to Overseas Shareholders, as outlined in Part II of the document.

Qualifying Shareholders should note that the Open Offer is not a rights issue and therefore the Offer Shares which are not applied for by Qualifying Shareholders will not be sold in the market for the benefit of the Qualifying Shareholders who do not apply. The Application Form is not a document of title and cannot be traded.

The Offer Shares will be issued credited as fully paid and free of all liens, charges and encumbrances and will, when issued, rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of their issue.

The Offer Price represents a discount of 0.02 pence (or approximately 33 per cent.) to the market price for Ordinary Shares of 0.06 pence on 24 January 2014, the latest practicable date before publication of this document.

For Qualifying Shareholders wishing to apply to subscribe for Offer Shares, completed Application Forms, accompanied by full payment in pounds sterling, should be returned by post or by hand (during normal business hours only) to Share Registrars Limited, Suite E, First Floor, 9 Lion and Lamb Yard, Farnham, Surrey GU9 7LL so as to arrive as soon as possible and in any event no later than 11 a.m. on 14 February 2014.

Further information on the Open Offer, including its terms and conditions and the detailed procedure for application and payment, is set out in Part II of this document.

Investing policy

On completion of the Open Offer the Company will advance its investing policy as set out in the circular to Shareholders dated 1 November 2013 and a number of businesses are already under consideration by the Board.

Risk Factors

Shareholders should consider fully the risk factors associated with the Open Offer. Your attention is drawn to the risk factors set out in Part III of this document.

Action to be taken in respect of the Open Offer

For details of the action to be taken in relation to the Open Offer, please refer to paragraph 3 of Part II of the document.

The last time for applications and accompanying payment under the Open Offer to be received by Share Registrars Limited is 11 a.m. on 14 February 2014.

If you are in any doubt about the contents of this document or about what action you should take, you are recommended immediately to seek your own independent financial advice from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser authorised under FSMA.

Further Information

Your attention is drawn to the further information set out in Parts II to IV of the document.

Recommendation

The Directors recommend that Qualifying Shareholders take up their rights under the Open Offer.

 

Yours sincerely

 

Adam Reynolds

Chairman

Ducat Ventures Plc

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ODPEAKFEDDKLEFF
Date   Source Headline
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSDirectorate Change
9th Dec 20207:00 amRNSProposed Director appointment and Director change
18th Nov 20207:00 amRNSLicense and supply agreement with Genuine Health
12th Oct 20207:00 amRNSLaunch of weight management products
9th Oct 20202:00 pmRNSInvestor presentation
8th Oct 20207:00 amRNSHead of Quality & Operations appointment
6th Oct 20207:00 amRNSExclusive distribution agreement
5th Oct 202011:05 amRNSSecond Price Monitoring Extn
5th Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSFDA Investigational New Drug authorisation
28th Sep 20207:00 amRNSExclusive distribution agreement
24th Sep 20207:00 amRNSHalf-year Report
22nd Sep 20207:00 amRNSLicense agreement for SlimBiome® Medical in the US
17th Sep 20207:00 amRNSDistributor agreement with Ayalla Marketing
15th Sep 202011:06 amRNSSecond Price Monitoring Extn
15th Sep 202011:00 amRNSPrice Monitoring Extension
15th Sep 20207:00 amRNSSweetBiotix sweet fibres agreement
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
3rd Sep 202011:05 amRNSSecond Price Monitoring Extn
3rd Sep 202011:00 amRNSPrice Monitoring Extension
11th Aug 20207:00 amRNSScientific and commercial development update
5th Aug 20207:00 amRNSExtension of terms for OptiBiome with OptiPharm
30th Jul 20207:00 amRNSExtension of terms for WellBiome with Maxum Foods
23rd Jul 20207:00 amRNSExtension of terms for WellBiome with Agropur
20th Jul 20207:00 amRNSTrading and commercial update
16th Jul 20207:00 amRNSExtension of terms, territories and products
14th Jul 20207:00 amRNSExtension of terms for WellBiome
9th Jul 202011:29 amRNSResult of AGM
6th Jul 20207:00 amRNSExtension of terms for WellBiome
1st Jul 20207:00 amRNSDistribution agreement with Actial Farmaceutica
29th Jun 20207:00 amRNSLaunch of WellBiome
17th Jun 20207:00 amRNSNotice of AGM
3rd Jun 20207:00 amRNSExercise of Warrant
2nd Jun 20203:35 pmRNSGrant of Options
1st Jun 20203:45 pmRNSHolding(s) in Company
1st Jun 20207:00 amRNSCambridge Commodities appointment as distributor
28th May 20207:00 amRNSFinal Results
20th May 20207:00 amRNSLaunch of SlimBiome gummies in USA
18th May 20207:00 amRNSTrading and commercial update
11th May 20207:00 amRNSExclusive distribution agreement with MAXCARE Inc
5th May 20207:00 amRNSDistribution of products in China and Hong Kong
4th May 20207:00 amRNSNon-exclusive agreement with Smart For Life
17th Apr 20204:24 pmRNSHolding(s) in Company
17th Apr 202011:03 amRNSPlacing and Related Party Transaction

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.